Graham Capital Management’s Corcept Therapeutics CORT Stock Holding History

Graham Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-13,281	Closed	-$669K	–	1330
2024 Q4	$669K	Sell	13,281 -8,223	-38%	-$431K	0.01%	635
2024 Q3	$995K	Buy	21,504 +5,185	+32%	+$184K	0.02%	467
2024 Q2	$530K	Buy	+16,319	New	+$447K	0.01%	570
2024 Q1	–	Sell	-8,094	Closed	-$263K	–	1098
2023 Q4	$263K	Buy	+8,094	New	+$222K	0.01%	764
2023 Q1	–	Sell	-11,945	Closed	-$243K	–	1094
2022 Q4	$243K	Buy	+11,945	New	+$299K	0.01%	941
2022 Q2	–	Sell	-43,284	Closed	-$974K	–	1041
2022 Q1	$974K	Buy	+43,284	New	+$921K	0.03%	314

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Graham Capital Management's CORT Position: Q1 2025 in Review

Graham Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 13,281 shares — an estimated $669K sold.

Graham Capital Management first reported a position in CORT in Q1 2022 and held it in 6 quarters. The position peaked at $995K in Q3 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

Graham Capital Management reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
Graham Capital Management sold 13,281 Corcept Therapeutics shares in Q1 2025, an estimated $669K.
Graham Capital Management first reported a position in Corcept Therapeutics in Q1 2022 and held it in 6 quarters.
Graham Capital Management's Corcept Therapeutics position peaked at $995K in Q3 2024.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Graham Capital Management's 13F filing for Q1 2025, filed 15 May 2025.